Diluted EPS came in at $-1.03, missed the $-1.00 consensus by $0.03.
Trailing eight quarters through Q3 2024
Common questions about Processa Pharmaceuticals, Inc.'s Q3 2024 earnings report.
Processa Pharmaceuticals, Inc. (PCSA) reported Q3 2024 earnings on October 30, 2024 before market open.
Processa Pharmaceuticals, Inc. reported diluted EPS of $-1.03 for Q3 2024.
EPS missed the consensus estimate of $-1.00 by $0.03.
You can read the 10-Q periodic report (0001493152-24-043058) directly on SEC EDGAR. The filing index links above go to sec.gov.